Emerging Role of Hypomethylating Agents Based on Epigenetic Modifications in Relapsed Refractory Multiple Myeloma

Suvir Singh¹ Rintu Sharma¹

¹ Department of Clinical Haematology and Stem Cell Transplantation, Dayanand Medical College, Ludhiana, Punjab, India

Ind J Med Paediatr Oncol 2021;42:603–604.

Address for correspondence Suvir Singh, MD, DM, Department of Clinical Haematology and Stem Cell Transplantation, Dayanand Medical College, Ludhiana, 141001 Punjab, India (e-mail: suvirs@gmail.com).

Epigenetics is defined as changes in genetic function without alteration of the underlying genetic code.¹ Dysregulation of normal epigenetic control in plasma cells is being increasingly described with effects on disease pathogenesis, drug resistance, and plasma cell (PC) plasticity. Of all epigenetic processes, DNA methylation represents a realistic target due to a significant role in pathogenesis and easy availability of hypomethylating agents in routine practice.

The best described epigenetic modification in Multiple Myeloma (MM) included promoter region methylation of tumor suppressor genes. It is now clear that the overall methylation pattern in myeloma, as with several other malignancies, is that of global DNA hypomethylation and promotor region hypermethylation of tumor suppressor genes, leading to genomic instability and disease progression. In MM, the pattern of DNA methylation varies depending on the stage at which MM cell lines are studied. In an elegant analysis, PCs from patients with MGUS, Smouldering Multiple Myeloma, and MM are shown to demonstrate a serial increase in differentially methylated loci (DMLs) with disease progression.² These modifications also have a potential prognostic role. For instance, as described by Choudhary et al,³ Patterns of aberrant methylation can provide prognostic information in patients with newly diagnosed myeloma.

This mechanism has been exploited for evaluation of hypomethylating agents (HMAs) as potentially active agents in MM. As far back in 2008, azacytidine was shown to be active against MM cell lines in vitro by causing de methylation of p16, theoretically restoring its tumor suppressor function. Interestingly, exposure to azacytidine also inhibited interleukin (IL)-6 production which plays a key role in

end-organ damage mediated by plasma cells. Both these processes led to apoptosis of MM cells in vitro, indicating potential clinical utility.⁴ Azacytidine has also been shown to have synergistic activity with several chemotherapeutic agents used in MM. For instance, bortezomib and doxorubicin have been shown to sensitize PCs in MM to the effects of azacytidine by synergistic induction of double strand DNA breaks.⁵

A recent phase-1 clinical study in 2020 evaluated the utility of azacytidine in combination with lenalidomide for patients with relapsed/refractory myeloma with median of five lines of therapy. It was noted that azacytidine restored the sensitivity of plasma cells to lenalidomide by reactivation of pathways controlling plasma cell differentiation. This translated into an overall response rate of 22% and progression-free survival (PFS) of 3.1 months.⁶ Similar findings were noted by Kallf et al,⁷ With oral azacytidine enabling a median PFS of 2.6 months in patients with lenalidomide refractory myeloma.

Identification of this novel mechanism of disease pathogenesis provides a potentially new target in MM. This pathway is especially attractive, as HMAs have been in clinical use for over a decade for acute myeloid leukemia with excellent data on toxicity and clinical use. Although several questions concerning clinical implications of plasma cell DNA methylation remain unanswered, development of further clinical data can potentially provide us a new, inexpensive treatment option for patients with MM.

Conflict of Interest

None declared.

DOI <https://doi.org/10.1055/s-0041-1732821>.
ISSN 0971-5851.

© 2021. Indian Society of Medical and Paediatric Oncology. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

References

- 1 Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond. *Pharmacol Ther* 2017;173:118–134
- 2 Agirre X, Castellano G, Pascual M, et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. *Genome Res* 2015;25(04):478–487
- 3 Choudhury SR, Ashby C, Tytarenko R, Bauer M, Wang Y, Deshpande S, Den J, Schinke C, Zangari M, Thanendrarajan S, Davies FE. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. *Journal of hematology & oncology* 2020 Dec;13(01):1–5
- 4 Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. *Haematologica* 2008;93(06):860–869
- 5 Kiziltepe T, Hideshima T, Catley L, et al. 5-Azacitidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. *Mol Cancer Ther* 2007;6(06):1718–1727
- 6 Khouri J, Faiman BM, Grabowski D, et al. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. *Semin Hematol* 2021;58(01):45–55
- 7 Kalf A, Khong T, Mithraprabhu S, Bergin K, Reynolds J, Bowen KM, Thakurta A, Guzman R, Wang M, Couto S, Ren Y. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). *Leukemia & lymphoma* 2019 Jun11